← Eichor
Condition: Advanced Metastatic Urothelial Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Advanced Metastatic Urothelial Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Phase 1 · 1 location(s) · Emory University · NCT04878029Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma
Phase 2 · 1 location(s) · Yale University · NCT07048457Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Phase 1 · 6 location(s) · Deciphera Pharmaceuticals, LLC · NCT06966024Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · 10 location(s) · Nammi Therapeutics Inc · NCT06582017A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
Phase 4 · 13 location(s) · Astellas Pharma Global Development, Inc. · NCT06862219CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With
Phase 2 · 1 location(s) · Northwestern University · NCT05733000AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metasta
Phase 1/Phase 2 · 18 location(s) · Avenzo Therapeutics, Inc. · NCT07038343Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Phase 2 · 135 location(s) · Gilead Sciences · NCT03547973SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 1 · 12 location(s) · Aktis Oncology, Inc. · NCT07020117A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With C
Phase 1 · 41 location(s) · Genentech, Inc. · NCT05581004A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Phase 1 · 30 location(s) · Pfizer · NCT07090499Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
Phase 1 · 1 location(s) · Beijing Biotech · NCT07492628A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Phase 2 · 221 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04879329A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · 286 location(s) · Eli Lilly and Company · NCT07218380Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
Phase 2 · 1 location(s) · Fox Chase Cancer Center · NCT072219429MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Phase 3 · 1 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06592326DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.
Phase 4 · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06820255Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TRO
Phase 2 · 96 location(s) · AstraZeneca · NCT05489211A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresecta
Phase 3 · 1 location(s) · Shanghai Miracogen Inc. · NCT05754853Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Local
Phase 2 · 1 location(s) · Xiujuan Qu · NCT07506057GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Phase 1/Phase 2 · 12 location(s) · GI Innovation, Inc. · NCT04977453Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab fo
Phase 1 · 1 location(s) · LG Chem · NCT06332755Intervention of Bladder Cancer by CAR-T
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT03185468Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Phase 1 · 122 location(s) · Exelixis · NCT05176483FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Phase 1 · 82 location(s) · Eli Lilly and Company · NCT05614739Ivonescimab in the Treatment of Multiple Advanced Tumors
Phase 2 · 1 location(s) · Fudan University · NCT06683846
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.